Table 1.
Demographics and baseline characteristics in the overall study population, and in the subgroup of recently diagnosed, treatment-naive patients, by sNfL baseline high–low.
| All patients | Recently diagnosed, treatment-naive patients | |||
|---|---|---|---|---|
| Parameters | Low sNfL category (≤9.3 pg/ml) | High sNfL category (>9.3 pg/ml) | Low sNfL category (≤9.3 pg/ml) | High sNfL category (>9.3 pg/ml) |
| N=876* | N=870* | N=274* | N=302* | |
| Age (years) | 38.6 ± 8.5 | 37.8 ± 9.7 | 36.7 ± 8.8 | 35.9 ± 9.7 |
| Sex, female, n (%) | 588 (67.1) | 602 (69.2) | 180 (65.7) | 209 (69.2) |
| MS duration since first symptom (years) | 8.3 ± 7.3 | 7.9 ± 6.9 | 3.5 ± 4.4 | 3.1 ± 3.6 |
| Previously treated with DMT | 560 (59.2) | 573 (61.2) | – | – |
| Number of relapses in the year before the study | 1.2 ± 0.7 | 1.3 ± 0.7 | 1.3 ± 0.7 | 1.3 ± 0.7 |
| Time since onset of most recent relapse (months) | 7.8 ± 13.5 | 7.0 ± 9.4 | 5.8 ± 4.8 | 5.8 ± 5.7 |
| EDSS score | 2.8 ± 1.3 | 3.0 ± 1.4 | 2.2 ± 1.2 | 2.3 ± 1.2 |
| Normalized brain volume (cm3) | 1447.6 ± 74.8 | 1437.2 ± 81.0 | 1478.4 ± 64.9 | 1468.2 ± 71.1 |
| Number of Gd+ T1 lesions | 0.4 ± 1.2 | 2.6 ± 5.4 | 0.4 ± 1.0 | 2.6 ± 4.8 |
| Patients free of Gd+ T1 lesions, n (%) | 679 (77.5) | 383 (44.0) | 206 (75) | 116 (38) |
| T2 lesion volume (cm3) | 9.4 ± 10.6 | 16.7 ± 15.1 | 5.9 ± 7.2 | 12.3 ± 12.4 |
| sNfL (pg/ml), median | 6.76 | 14.23 | 6.77 | 15.29 |
The baseline sNfL level used for high–low stratification was assessed prior to first study treatment. Data are expressed as mean ± SD unless specified otherwise.
*Only patients with non-missing baseline NfL values are included.
EDSS, expanded disability status scale; Gd+, gadolinium-enhancing; SD, standard deviation; sNfL, serum neurofilament light chain.